Business
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 71st Annual Scientific Session & Expo (ACC.22) taking place in Washington, D.C. from April 2, 2022 - April 4, 2022. The presentations will include the full results from METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), a Phase 3 clinical trial omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, in a Late Breaking Clinical Trial Session, as well as the results from Cohort 3 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), the Phase 2 clinical trial of aficamten in patients with hypertrophic cardiomyopathy, in a moderated poster presentation. Late Breaking Clinical Trial Session Title: 406-10 – The Effect of Omecamtiv Mecarbil on Exercise Tolerance in Patients with Chronic Heart Failure and Reduced Ejection Fraction: METEORIC-HFPresenter: Michael Felker, M.D., Professor of Medicine, Duke Clinical Research InstituteDate: April 3, 2022Session Title: 406 - Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical TrialsPresentation Time: 9:45 – 9:55 AM ETLocation: Main Tent, Hall D Moderated Poster Presentations Title: 1005-17 – Efficacy and Safety of Aficamten and Disopyramide Coadministration in Obstructive Hypertrophic Cardiomyopathy: Results from REDWOOD-HCM Cohort 3Presenter: Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of PennsylvaniaSession Title: 1005 Progress in Diagnosis, Risk Stratification and Treatment of Hypertrophic CardiomyopathiesDate: April 2, 2022Presentation Time: 11:30-11:40 AM ETLocation: Heart Failure and Cardiomyopathies Moderated Poster Theater 12, Hall C Title: 1114-07 – Healthcare Resource Use, Intensity and Costs among Patients with Heart Failure with Reduced Ejection Fraction Treated with Omecamtiv Mecarbil in GALACTIC-HFPresenter: Nihar R. Desai, M.D., MPH, Associate Professor of Medicine, Associate Chief, Cardiovascular Medicine, Yale School of Medicine, Center for Outcomes Research and EvaluationSession Title: 1114 - New Analyses from Heart Failure Clinical ...